Category: Latest News
-
Wall Street Set for Higher Open as Oil Prices Tumble on Iran Diplomacy Hopes: Dow Jones, S&P, Nasdaq, Futures
U.S. stock index futures pointed to a stronger open on Monday, with investors expected to build on last week’s gains as a sharp decline in crude oil prices improved overall market sentiment. The drop in oil followed renewed optimism over diplomatic efforts in the Middle East after U.S. President Donald Trump announced he had called…
-
Indivior Shares Surge After Strong Quarterly Results and Higher 2026 Outlook
Indivior Pharmaceuticals Inc. (NASDAQ:INDV) reported better-than-expected second-quarter 2026 results on Monday, driven by record sales of its opioid use disorder treatment SUBLOCADE, while raising its full-year financial guidance. The stronger outlook sent the pharmaceutical company’s shares up 9.22% in pre-market trading. Earnings and Revenue Top Expectations Indivior posted adjusted earnings of $1.15 per share for…
-
Genprex Shares Rise After Collaboration With Roche Diagnostics
Genprex Inc. (NASDAQ:GNPX) shares gained 3% on Monday after the clinical-stage biotechnology company announced a collaboration with Roche Diagnostics to validate biomarkers designed to improve patient selection in clinical trials for non-small cell lung cancer (NSCLC). Partnership Focuses on Biomarker Validation The collaboration will focus on validating the use of TROP2 as a biomarker to…
-
CeriBell Shares Gain After Medicare Approves Additional Payment for Delirium Monitoring System
CeriBell Inc. (NASDAQ:CBLL) shares climbed about 3% after the company announced that the U.S. Centers for Medicare & Medicaid Services (CMS) approved a New Technology Add-on Payment (NTAP) for its Delirium Monitor System. Medicare to Provide Additional Reimbursement Under the NTAP approval, hospitals may receive up to $2,171 in additional reimbursement for each eligible Medicare…
-
Twist Bioscience Shares Decline Following Quarterly Earnings Miss
Twist Bioscience (NASDAQ:TWST) shares fell 4.2% in pre-market trading after the synthetic biology company reported fiscal third-quarter results that exceeded revenue expectations but fell short of Wall Street’s earnings forecast. The mixed performance prompted investors to focus on the company’s continued profitability challenges despite solid top-line growth. Revenue Beats Expectations, but Earnings Disappoint Twist Bioscience…
-
FDA Awards Breakthrough Therapy Designation to Lilly’s Olomorasib for Pancreatic Cancer
Eli Lilly and Company (NYSE:LLY) has received Breakthrough Therapy designation from the U.S. Food and Drug Administration for its investigational drug olomorasib as a standalone treatment for adults with advanced pancreatic cancer carrying a KRAS G12C mutation who have previously received at least one systemic therapy. The designation is intended to accelerate the development and…
-
Nexera Technologies Pursues Exclusive Distribution Rights for Darknet Intelligence Platform
Nexera Technologies Ltd. (NASDAQ:NEXR) has entered into a letter of intent with Nebo Holdings Limited that could see the company become the exclusive global reseller and distributor of Preempt OSINT, a cybersecurity platform designed to monitor darknet activity. The proposed partnership would expand Nexera’s cybersecurity offering by giving it exclusive rights to commercialize the platform…
-
Sportradar Shares Drop After Earnings Miss and Lower-Than-Expected Outlook
Sportradar Group AG (NASDAQ:SRAD) reported second-quarter 2026 results on Monday that fell short of analyst expectations on both earnings and revenue, while its full-year guidance also disappointed investors. The sports technology company’s shares declined 13.20% in pre-market trading following the earnings release. Earnings and Revenue Miss Wall Street Forecasts Sportradar reported adjusted earnings of €0.00…
-
Krystal Biotech Shares Slide Despite Earnings Beat as Revenue Misses Forecasts
Krystal Biotech, Inc. (NASDAQ:KRYS) reported second-quarter 2026 results on Monday that exceeded earnings expectations but fell short of Wall Street’s revenue estimates, sending the stock down 7.65% in pre-market trading. Earnings Outperform While Revenue Comes in Below Expectations The company reported adjusted earnings of $1.79 per share for the second quarter, beating analysts’ consensus estimate…
-
Supernus Shares Jump After Revenue Beat, Higher Guidance and Indivior Merger Announcement
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) reported second-quarter 2026 results on Monday that fell short of earnings expectations but exceeded revenue forecasts, while also announcing a merger agreement with Indivior Pharmaceuticals (NASDAQ:INDV). The combination of stronger sales, improved guidance and the proposed transaction sent Supernus shares up 18.75% in pre-market trading. Revenue Tops Expectations Despite Earnings Loss…